Successful second implant of NTCELL for Parkinson’s

Living Cell Technologies Limited

CAN: 104 028 042

ASX: LCT

OTCQX: LVCLY

ASX ANNOUNCEMENT

Successful second implant of NTCELL for Parkinson’s

18 August 2014 – Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited today announced that a second patient has been successfully implanted at Auckland City Hospital in the clinical trial of the regenerative cell therapy NTCELL® for Parkinson’s disease. LCT plans to complete the patient treatment phase of the study this year.

The Phase I/IIa clinical trial is an open-label investigation of the safety and clinical effects of NTCELL in patients who can no longer respond to current therapy. The trial is directed by Dr Barry Snow MBChB, FRACP, FRCPC, an internationally recognised clinician and researcher in Parkinson’s disease who leads the Auckland Movement Disorders Clinic at the Auckland District Health Board.

Dr Ken Taylor, CEO of LCT says, “A great deal of hard work, preclinical research and scientific endeavour has gone into the discovery and development of NTCELL. Our innovative approach is the first to target regeneration of brain cells for patients who are failing the current conventional treatment for Parkinson’s disease.”

– Ends –

For further information: www.lctglobal.com

© Scoop Media